The LEPRA Society, with a legacy of 100 years, continues its transformative journey of combating neglected diseases and reducing disabilities among marginalized populations in India. Through innovative programs like the DISPELL initiative, supported by Mankind Pharma, LEPRA has reaffirmed its dedication to empowering communities and dismantling the stigma surrounding diseases like leprosy, lymphatic filariasis (LF), and others. Operating across 140 districts in 10 states, LEPRA has made strides in improving healthcare access, fostering dignity, and ensuring holistic development for individuals and families impacted by these conditions.

Mankind Pharma’s partnership in the DISPELL project has been instrumental in advancing LEPRA’s objectives. This initiative focuses on early case detection, comprehensive disability care, and skill-building for healthcare providers, alongside providing socio-economic support and education. Through targeted interventions and community engagement, the project has brought essential services closer to those in need while enhancing the capacity of government and private health systems to deliver sustainable care.

DISPELL: Advancing Disability Prevention and Empowerment

The DISPELL (Disability Prevention & Empowerment of Leprosy and LF Patients) project, bolstered by Mankind Pharma’s support, represents a milestone in disability care. Over the past quarter, the program has achieved remarkable progress in early detection and treatment of leprosy and LF across Andhra Pradesh, Delhi, Odisha, Telangana, and more. By strengthening Comprehensive Disability Care Centres (CDCCs) and fostering local health partnerships, the initiative has expanded access to treatment and rehabilitation services.

Key achievements include distributing customized footwear to over 600 patients, providing self-care kits to nearly 400 individuals, and referring multiple cases for advanced reconstructive surgeries and hydrocele interventions. Through these efforts, the project has significantly improved mobility, reduced disabilities, and empowered patients to lead dignified lives. The proactive approach of engaging communities, educating health workers, and offering socio-economic aid, such as funding small businesses and linking beneficiaries to welfare schemes, underscores the comprehensive nature of the initiative.

Leprosy and LF Interventions: Creating a Ripple Effect

Focused interventions under the leprosy and LF programs have showcased the power of community awareness, healthcare training, and patient-centric care. The LF program’s innovative approaches—such as mass drug administration and patient education—have reached over 15,000 individuals, while the leprosy program has screened 81,000 people for early detection, reducing the likelihood of advanced disabilities.

The provision of lightweight, customized footwear and self-care kits exemplifies how practical solutions can improve quality of life. Linking patients to social welfare schemes and educating them on their rights has furthered socio-economic stability, ensuring a holistic support system. Mankind Pharma’s support has been pivotal in these areas, reinforcing the sustainability and scalability of these health initiatives.

A Vision for the Future

As LEPRA Society looks forward, the lessons learned from its journey are being channeled into robust strategies for expanding outreach, strengthening partnerships, and leveraging digital tools. By integrating advanced training programs, improving monitoring mechanisms, and fostering sustainable community-based models, the society is poised to enhance its impact, ensuring a brighter, healthier future for all.